Jakarta, CNBC Indonesia – Composite Stock Price Index (IHSG) on perdagangan Wednesday (9/9/20) atLid down by almost 2% or rather 1,81% at level 5.149,37 after being dragged into the action profit taking on US stock exchanges which also exacerbated Asian Stocks and negative sentiment on problematic vaccine trials.
Trade data noted that foreign investors made net selling of Rp 591 billion in the regular market today with today’s transaction value touching Rp. 7, 4 trillion.
The stock that has been sold most by foreigners today is PT Bank Independent Tbk (BMRI) with a net sale of IDR 89 thousandand and PT Bank Rakyat Indonesia Tbk (BBRI) who recorded net sell amounting to Rp 128 billion.
Meanwhile saham the most dikoleksi foreigners today are PT Sarana Menara Nusantara Tbk (TOWR) with a net purchase of Rp. 40 thousandand and PT H M Sampoerna Tbk (HMSP) with net buy Rp. 12 billion.
Further exchanges in the Asian region observed subsidence, Nikkei in Japan detectedpresses 1,04%, The Hang Seng Index in Hong Kong is down 0,63%, sedangkan Index STI in Singapore it fell 0.27%.
From within the country, WITH A report retail sales as reflected by the Retail Sales Index (IPR) contracted 12.3% in July 2020 compared to the same period the previous year (year-on-year/ YoY). Retail sales have not escaped the eight straight months of contraction.
Even in August 2020, BI estimates that retail sales will still decline with an IPR contraction of 10.1% YoY. By doing so, the chain of retail sales contraction is getting longer to nine consecutive months.
The good news is that the contraction in retail sales continues to decline. Since touching the ‘crust of hell’ in May 2020, the rate of decline in IPR has gradually dwindled.
“Sales improvement is predicted for almost all commodity groups surveyed, with sales in the Food, Beverage and Tobacco group experiencing the lowest contraction, with a growth of -1.9% YoY. This is in line with the increase in people’s purchasing power and the implementation of New Habit Adaptation. (AKB), “wrote the BI report.
Furthermore, negative sentiment on global markets emerged from kabar surprised from AstraZeneca’s Covid-19 vaccine developer. The company, which is working with the University of Oxford, will have to end its final stage clinical trials indefinitely.
The discontinuation of the clinical trial of the coronavirus vaccine candidate AZD1112 follows reports of the severe negative impact of a clinical trial of the vaccine on a participant in the UK.
For information, the AstraZeneca vaccine candidate entered the stage III (final) clinical trial starting last month after the results of the phase I and II clinical trials showed encouraging signs.
RESEARCH TEAM CNBC INDONESIA
(trp/trp)
– .
